Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution
about
Monomeric human cathepsin ECrystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug designStructure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparumMolecular mechanisms for the conversion of zymogens to active proteolytic enzymesStructural Insights into Central Hypertension Regulation by Human Aminopeptidase AHigh-resolution X-ray diffraction study of the complex between endothiapepsin and an oligopeptide inhibitor: the analysis of the inhibitor binding and description of the rigid body shift in the enzymeCrystallographic studies on the binding modes of P2-P3 butanediamide renin inhibitorsX-ray-crystallographic studies of complexes of pepstatin A and a statine-containing human renin inhibitor with endothiapepsinThe aspartic proteasesAliskiren: the first renin inhibitor for clinical treatmentAnalysis of crystal structures of aspartic proteinases: on the role of amino acid residues adjacent to the catalytic site of pepsin-like enzymesOverview of protein structural and functional folds.Human napsin A: expression, immunochemical detection, and tissue localization.The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region.Spectrum of mutations in the renin-angiotensin system genes in autosomal recessive renal tubular dysgenesis.Aliskiren displays long-lasting interactions with human renin.Renin and cardiovascular disease: Worn-out path, or new direction.Evaluating molecular mechanism of hypotensive peptides interactions with renin and angiotensin converting enzymeCloning and nucleotide sequence of the cyclic AMP receptor protein-regulated Salmonella typhimurium pepE gene and crystallization of its product, an alpha-aspartyl dipeptidase.The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins.The molecular biology of human renin and its gene.The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.Comparative modeling of proteins in the design of novel renin inhibitors.New roles for renin and prorenin in heart failure and cardiorenal crosstalk.Molecular dynamics studies on both bound and unbound renin protease.Expression of soluble cloned porcine pepsinogen A in Escherichia coli.Aspartic proteinases: Fourier transform infrared spectroscopic studies of a model of the active side.Deglycosylation of proteins for crystallization using recombinant fusion protein glycosidases.Is the pseudo-dyad in retroviral proteinase monomers structural or evolutionary?Renin inhibition by soyasaponin I: a potent native anti-hypertensive compound.The development of the direct renin inhibitor aliskiren: treating hypertension and beyondThe catalytic mechanism of mouse renin studied with QM/MM calculations
P2860
Q24322889-1EC17D5E-9245-4DCF-9D1A-DE817EB05441Q24562097-FB54EA42-2EE8-4F69-931C-FEAB24CD2334Q24597864-5A8EF62B-A7AB-41E2-9368-70B18559FDAAQ24673104-6BD192DB-9E80-45A2-A3AB-6ED0D5AD0988Q27679202-390168BC-0575-4CC5-B648-CD8E788AFDA8Q27703612-0A548891-83DE-45ED-B66A-D79E3B052DCDQ27729320-FDB19B11-A532-4652-9A96-4F46182B342DQ27732078-97DB2B38-CC1F-408B-BC12-783797F3A2A1Q28208915-3777279E-0BA5-4AF4-B1DE-2FBF0CBAD892Q28272666-262B5B25-D56C-4E75-B3ED-331B16C6CF36Q28364502-B1263A38-EC5A-4356-9D47-FA8A4E876D5BQ30368988-D4A2D378-5677-463F-A4C5-E1FFD7DD495AQ33882077-20EFCE14-6596-4C94-B0B4-68EAF5A8CD24Q33890879-2175C3D1-F4AE-4F10-8410-270C0354A537Q34077532-3100567A-7629-4183-ADC0-B05DD3666914Q34109516-B80EC294-B31C-4281-AE61-BB6C2472DF01Q34801804-48768DBC-F1D7-4DF3-83EA-58C39631ED1FQ35112957-B2F9B9A4-F5BC-456B-B4CE-6E6BB6A0D1BEQ36104485-7076A1FF-50A9-468D-9E8C-27918E5CB518Q36604792-B65055CF-73D3-4564-8004-C82504D703E9Q36987887-894EB402-FBB4-4517-98F8-5E7A61B380FDQ37019887-9D24F98D-AB5F-4689-8724-3121FCC646BFQ37253693-7EE06184-2449-4A0C-A4D6-765BFE578F7AQ37893014-6443F727-E0DF-409D-9B08-077BB563614BQ39445512-B013D129-F0D3-4F13-90BD-654B665B8D74Q41990660-05FA11EE-27EB-4BC3-97B9-A45B3BFD9B71Q42109945-60B5CF31-7DE6-4235-8B2C-5E12E66201FCQ42845097-C4B45E3D-7D02-47CB-A16D-1DB9BC43617DQ43936629-3A51F476-106F-4207-B969-81ADB91CE955Q52748058-E109CC0A-92DC-4652-B880-5CBA2B308171Q56883123-EA783663-38F8-40FC-854B-A6341FBEADE9Q57991038-2D71839C-E026-427A-9C7A-D66B68949C1A
P2860
Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution
description
1989 nî lūn-bûn
@nan
1989 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մարտին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Structure of recombinant human ...... ive drugs, at 2.5 A resolution
@ast
Structure of recombinant human ...... ive drugs, at 2.5 A resolution
@en
Structure of recombinant human ...... ive drugs, at 2.5 A resolution
@nl
type
label
Structure of recombinant human ...... ive drugs, at 2.5 A resolution
@ast
Structure of recombinant human ...... ive drugs, at 2.5 A resolution
@en
Structure of recombinant human ...... ive drugs, at 2.5 A resolution
@nl
prefLabel
Structure of recombinant human ...... ive drugs, at 2.5 A resolution
@ast
Structure of recombinant human ...... ive drugs, at 2.5 A resolution
@en
Structure of recombinant human ...... ive drugs, at 2.5 A resolution
@nl
P2093
P356
P1433
P1476
Structure of recombinant human ...... ive drugs, at 2.5 A resolution
@en
P2093
A R Sielecki
C T Carilli
J A Lewicki
J D Baxter
K Hayakawa
M E Murphy
M Fujinaga
P304
P356
10.1126/SCIENCE.2493678
P407
P577
1989-03-10T00:00:00Z